Welcome to our dedicated page for THERIVA BIOLOGICS SEC filings (Ticker: TOVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Theriva Biologics, Inc. (TOVX) SEC filings page provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information about Theriva’s clinical-stage programs, capital structure, and corporate actions, complementing its press releases and scientific presentations.
Investors can review Form 10-K and Form 10-Q annual and quarterly reports for discussions of risk factors, research and development activities, and financial condition related to programs such as VCN-01, SYN-004 (ribaxamase), SYN-020, and the VCN-X discovery efforts. Current reports on Form 8-K describe material events, including clinical data announcements, regulatory feedback from agencies such as the European Medicines Agency, warrant inducement agreements, public offerings, and at-the-market sales agreements.
Theriva’s proxy statements on Schedule 14A outline matters submitted to stockholders, such as proposals to approve the issuance of additional common shares upon exercise of warrants issued in private placements. These documents explain voting mechanics, record dates, and the rationale for share authorization requests tied to financing transactions.
Forms related to securities offerings, such as registration statements and prospectus supplements referenced in 8-K filings, describe the terms of public offerings of common stock and warrants, as well as at-the-market programs through placement agents. Together, these filings help clarify how Theriva funds the development of its clinical pipeline.
On this page, Stock Titan pairs Theriva’s SEC filings with AI-powered summaries that highlight key points, such as changes in capital structure, new clinical or regulatory disclosures, and important risk factor updates. Real-time updates from EDGAR, along with structured access to historical filings, allow users to monitor how Theriva’s regulatory and financing profile evolves alongside its investigational therapies.
Theriva Biologics, Inc. (TOVX) filed a Form S-8 to register shares for its employee benefit plan and related amendments. After prior registrations and two reverse stock splits (a 1-for-10 in
Theriva Biologics, Inc. filed a report describing new communications about its oncolytic virus pipeline. On October 6, 2025, the company issued a press release announcing the presentation of preclinical data for VCN-12, a next-generation oncolytic adenovirus from its VCN-X discovery program, at the 32nd Annual Congress of the European Society of Gene & Cell Therapy.
The same press release, and an additional disclosure, highlighted publication of results from a preclinical study by collaborators at the University of Navarra on intracranial administration of VCN-01, which supports further development of VCN-01 as a potential treatment for brain tumors. The information related to the press release is furnished, not filed, and is not incorporated by reference into other SEC filings.
Theriva Biologics, Inc. approved a restructuring plan on September 28, 2025 to resize the company and focus resources on business development, licensing, and upcoming regulatory meetings for its lead oncolytic virus candidate VCN-01 in metastatic pancreatic ductal adenocarcinoma and retinoblastoma.
As part of the plan, Theriva implemented a workforce reduction on September 30, 2025, eliminating approximately seven positions, or about 32% of its global workforce. The company expects to record about $520,000 of charges in the fourth quarter of 2025, primarily for cash severance and benefits over roughly three months.
The restructuring is expected to reduce annual compensation and benefits costs by about $2.0 million. Together with additional anticipated operating cost reductions, Theriva believes this will extend its cash runway into the second quarter of 2026, though it cautions that actual charges and savings may differ materially due to legal and operational factors.
Theriva Biologics, Inc. reported results of its 2025 annual stockholder meeting held on August 29, 2025. Stockholders approved Amendment No. 3 to the 2020 Stock Incentive Plan, increasing the number of shares of common stock the company may grant under the plan from 2,500,000 to 4,500,000, expanding the pool available for equity-based compensation.
Four directors – Jeffrey J. Kraws, Steven A. Shallcross, John Monahan and Jeffrey Wolf – were re-elected to serve until the next annual meeting. Stockholders also ratified BDO USA, P.C. as independent registered public accounting firm for the year ending December 31, 2025, approved on an advisory basis the compensation of named executive officers, and supported holding future advisory votes on executive pay every three years. The board determined to follow the three-year frequency in line with this vote.
Theriva Biologics, Inc. filed a Form 10-Q reporting total assets of $35.83 million and cash and cash equivalents of $12.12 million as of June 30, 2025. The company recorded a quarterly net loss of $13.06 million and a six-month net loss of $17.38 million, driven by a sharp increase in general and administrative expenses and continued R&D spending. In the period the company met primary survival and safety endpoints in its VIRAGE Phase 2b trial for lead candidate VCN-01, which triggered a contractual milestone obligation and contributed to an increase in contingent consideration to $10.16 million. The acquired in-process R&D (IPR&D) asset is carried at $19.62 million and was tested for impairment with no charge recorded. The company raised gross proceeds of approximately $7.5 million in a May 2025 offering and had cash of about $9.5 million in early August 2025, with management stating that current cash is expected to be sufficient into the first quarter of 2026. The 10-Q discloses substantial doubt about the Company’s ability to continue as a going concern and the need to obtain additional financing or strategic transactions to fund planned clinical activities.
Theriva Biologics, Inc. furnished a press release containing financial information for the quarter ended June 30, 2025, and attached that press release to this Current Report as Exhibit 99.1. The report also identifies an interactive data file as Exhibit 104.
The company states that the information in Item 2.02 and the attached press release is furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other SEC filings. The Form 8-K is signed by Steven A. Shallcross, Chief Executive Officer and Chief Financial Officer. No financial figures are included in the Form text provided here.